Insomnia<unk>  receptor antagonists dose-dependently improve sleep parameters including latency to persistent sleep (LPS), wake after sleep onset (WASO), sleep efficiency (SE), total sleep time (TST), and sleep quality (SQ). Network meta-analyses have found that<unk>  receptor antagonists including suvorexant and lemborexant are more effective in the treatment of insomnia than other sleep aids including benzodiazepines (e.g., triazolam, temazepam), Z-drugs (e.g., zolpidem, zopiclone), antihistamines (e.g., doxepin, diphenhydramine, doxylamine), antidepressants (e.g., trazodone, mirtazapine, amitriptyline), anticonvulsants (e.g., gabapentin, pregabalin), and melatonin receptor agonists (e.g., melatonin, ramelteon).<unk>  receptor antagonists are not currently used as first-line treatments for insomnia due to cost and concerns about possible misuse liability. Delirium Suvorexant appears to be effective in the prevention of delirium.
Orexin antagonist
Steroidogenesis inhibitor
Dopamine agonist
Dopamine antagonist
Antiglucocorticoid
Neurosteroidogenesis inhibitor
Nerve growth factor inhibitor
Alpha-adrenergic agonist